Variable | Number | % |
---|---|---|
Breast cancer type | ||
Ductal | 98 | 82 |
Lobular | 10 | 8 |
Ductal/lobular | 2 | 2 |
Uncertain | 4 | 3 |
Other | 5 | 4 |
Grade | ||
1 | 6 | 5 |
2 | 41 | 34 |
3 | 56 | 47 |
Unknown | 17 | 14 |
ER | ||
Positive | 51 | 42 |
Negative | 69 | 57 |
PR | ||
Positive | 40 | 34 |
Negative | 78 | 65 |
Not determined | 1 | 1 |
HER2 | ||
Positive (IHC3+) | 51 | 42 |
Positive (IHC2+ and FISH+) | 6 | 5 |
Negative | 62 | 52 |
Not determined | 1 | 1 |
Chemotherapy before brain metastases | ||
Yes, adjuvant, neoadjuvant | 47 | 39 |
Yes, for metastatic disease | 9 | 7 |
Yes, a combination thereof | 47 | 39 |
No | 8 | 7 |
Unknown | 9 | 7 |
Endocrine therapy before brain metastasesb | ||
Yes, adjuvant, neoadjuvant | 31 | 26 |
Yes, for metastatic disease | 5 | 4 |
Yes, a combination thereof | 13 | 11 |
No | 66 | 55 |
Unknown | 5 | 4 |
Trastuzumab before brain metastasesc | ||
Yes | 30 | 53 |
No | 25 | 43 |
Unknown | 2 | 3 |
Chemotherapy after brain surgery | ||
Yes | 57 | 47 |
No | 47 | 39 |
Unknown | 16 | 13 |
Endocrine therapy after brain surgeryb | ||
Yes | 21 | 17 |
No | 86 | 72 |
Unknown | 13 | 11 |
Anti-HER2 therapy after brain surgeryc | ||
Trastuzumab | 9 | 16 |
Lapatinib | 7 | 12 |
Sequentially both | 3 | 5 |
Type of first progression | ||
Local | 2 | 2 |
Regional | 9 | 7 |
Distant | 106 | 88 |
Combined local regional and/or distant | 1 | 1 |
Unknown | 1 | 2 |
Dominant site of metastatic diseased | ||
Soft tissue | 3 | 2 |
Bone | 5 | 4 |
Visceral | 110 | 92 |
Unknown | 2 | 2 |
Age at breast cancer diagnosis (mean (range) years) | 49 (26-80) | |
Age at brain metastasis surgery (mean (range) years) | 52 (29-83) |